Press Release: Novartis receives positive CHMP -2-

References

1. Metz M, Giménez-Arnau A, Hide M, et al. Long-term efficacy and

safety of remibrutinib in patients with chronic spontaneous urticaria in

the Phase 3 REMIX-1 and REMIX-2 studies. Presented as a late oral

abstract session on clinical trials at EAACI 2024; May 31-June 3, 2024;

Valencia, Spain

2. Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, Zuberbier T,

Keil T. Prevalence of chronic urticaria in children and adults across the

globe: Systematic review with meta-analysis. Allergy.

2020;75(2):423--432. doi:10.1111/all.14037

3. Worldometer. Europe Population (2025). Available at:

https://www.worldometers.info/population/europe/ [Last accessed February

2026]

4. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in

chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy

2011; 66: 317-330.

5. Maurer M, Berger W, Giménez-Arnau A, et al. Remibrutinib, a novel

BTK inhibitor, demonstrates promising efficacy and safety in chronic

spontaneous urticaria. J Allergy Clin Immunol 2022; 150: 1498-1506.

6. Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (remibrutinib),

a potent and highly selective covalent inhibitor of Bruton's Tyrosine

Kinase. J Med Chem 2020; 63: 5102-5118.

7. Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of

chronic urticaria and angioedema. Clin Exp Allergy 2015; 45: 547-565.

8. Jain V, Giménez-Arnau A, Hayama K, et al. Remibrutinib demonstrates

favorable safety profile and sustained efficacy in chronic spontaneous

urticaria over 52 weeks. J Allergy Clin Immunol 2024; 153: 479-486.

9. Patient. Antihistamines. Last updated 12 October 2022. Available from:

https://patient.info/allergies-blood-immune/allergies/antihistamines [Last

accessed: February 2026].

10. ClinicalTrials.gov. NCT03827798. Study of efficacy and safety of

investigational treatments in patients with moderate to severe

hidradenitis suppurativa. Available

from: https://clinicaltrials.gov/ct2/show/NCT03827798. [Last accessed:

February 2026]

11. ClinicalTrials.gov. NCT05432388. Study of efficacy, safety and

tolerability of remibrutinib in adult participants with an allergy to

peanuts. Available

from: https://clinicaltrials.gov/study/NCT05432388 [Last accessed:

February 2026].

12. ClinicalTrials.gov. NCT05147220. Efficacy and safety of remibrutinib

compared to teriflunomide in participants with relapsing multiple

sclerosis (RMS) (REMODEL-1). Available

from: https://clinicaltrials.gov/study/NCT05147220 [Last accessed:

February 2026].

13. ClinicalTrials.gov. NCT05156281. Efficacy and safety of remibrutinib

compared to teriflunomide in participants with relapsing multiple

sclerosis (RMS) (REMODEL-2). Available from:

https://clinicaltrials.gov/study/NCT05156281 [Last accessed: February

2026].

14. ClinicalTrials.gov. NCT05030311. A Phase 3 study of efficacy and safety

of remibrutinib in the treatment of CSU in adults inadequately controlled

by H1 antihistamines (REMIX-1). Available from:

https://clinicaltrials.gov/study/NCT05030311 [Last accessed February,

2026].

15. ClinicalTrials.gov. NCT05032157. A Phase 3 study of efficacy and safety

of remibrutinib in the treatment of CSU in adults inadequately controlled

by H1- antihistamines (REMIX-2). Available from:

https://clinicaltrials.gov/study/NCT05032157 [Last accessed February,

2026].

16. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international

EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition,

classification, diagnosis, and management of urticaria. Allergy 2022; 77:

734-766.

17. The World Bank. Population, total. Available from:

https://data.worldbank.org/indicator/SP.POP.TOTL [Last accessed: February

2026].

18. AAAAI (American Academy of Allergy, Asthma & Immunology). Hives

(urticaria) and angioedema overview. Available from:

https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/hives-(urticaria)-and-angioedema-overview

[Last accessed: February 2026].

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

February 27, 2026 06:28 ET (11:28 GMT)